Response dynamics in chronic-phase chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Complete cytogenetic response (CCyR) is a critical indicator of survival in chronic-phase chronic myeloid leukemia (CP-CML).
• Timely achievement of CCyR signifies a treatment-sensitive disease, influencing clinical management guidelines.
• European LeukemiaNet and NCCN guidelines recommend alternative therapies for patients not achieving CCyR within 6-12 months.

Purpose of the Study:

• To emphasize the significance of CCyR as a surrogate for long-term survival in CP-CML.
• To discuss treatment strategies for patients failing to achieve CCyR on standard imatinib therapy.
• To highlight the role of cytogenetic testing in CML management.

Main Methods:

• Review of clinical trial data and established treatment guidelines.
• Analysis of the association between CCyR achievement, duration, and patient survival.
• Evaluation of treatment options for imatinib-refractory or intolerant patients.

Main Results:

• Early CCyR achievement is linked to the best benefit:risk ratio, minimizing progression risk.
• The duration of CCyR impacts disease progression.
• Cytogenetic testing remains a cornerstone of CML care, especially early in treatment.

Conclusions:

• CCyR is the most important surrogate marker for long-term survival in CP-CML.
• Management of CML requires timely cytogenetic assessment to guide therapy adjustments.
• Further data are needed to confirm CCyR's role in patients treated with newer tyrosine kinase inhibitors.